{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:33:22Z","timestamp":1783020802191,"version":"3.54.6"},"reference-count":43,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100015841","name":"Nordic Nanovector","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["182880"],"award-info":[{"award-number":["182880"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["205601"],"award-info":[{"award-number":["205601"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:sup>177<\/jats:sup>\n                    Lu\u2010lilotomab satetraxetan (Betalutin) is an anti\u2010CD37 radioimmunoconjugate evaluated as a single administration therapy for the treatment of patients with relapsed\/refractory follicular lymphoma or diffuse large B\u2010cell lymphoma (DLBCL).\n                    <jats:sup>177<\/jats:sup>\n                    Lu\u2010lilotomab satetraxetan treatment is well tolerated and shows consistent activity in most of the patients evaluated so far. Herein, we investigated the activity of\n                    <jats:sup>177<\/jats:sup>\n                    Lu\u2010lilotomab satetraxetan in a panel of 55 lymphoma cell lines of B\u2010 and T\u2010cell origin. CD37\u2010targeted radioimmunotherapy was more effective in CD37\u2010positive B\u2010cell lymphomas (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200946) than in CD37\u2010negative T\u2010cell lymphomas (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20099). Focusing on DLBCL cell lines, mutations such as\n                    <jats:italic>BCL2<\/jats:italic>\n                    or\n                    <jats:italic>MYC<\/jats:italic>\n                    translocations were not correlated to sensitivity. However,\n                    <jats:italic>BCL2<\/jats:italic>\n                    expression was higher in resistant than in sensitive GCB\u2010DLBCL cell lines, and the addition of the BCL2 inhibitor venetoclax showed synergism when added to the radioimmunoconjugate. Finally, the pattern of activity of\n                    <jats:sup>177<\/jats:sup>\n                    Lu\u2010lilotomab satetraxetan differed from what was achieved with a CD37\u2010targeting antibody\u2013drug conjugate or with Rituximab cyclophosphamide hydroxydaunorubicin (doxorubicin) oncovin prednisone (R\u2010CHOP), indicating the potential benefit of the beta\u2010emitter payload. This systematic analysis of the responsiveness of lymphoma cell lines to CD37\u2010targeting radioimmunotherapy consolidated\n                    <jats:sup>177<\/jats:sup>\n                    Lu\u2010lilotomab satetraxetan as a promising compound for the treatment of CD37\u2010positive malignancies and identified candidate biomarkers and co\u2010targets to detect and overcome cancer cell\u2010intrinsic resistance mechanisms.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70143","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:54:46Z","timestamp":1758243286000},"page":"1855-1862","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive analysis of\n                    <scp>\n                      <sup>177<\/sup>\n                      Lu\n                    <\/scp>\n                    \u2010lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes"],"prefix":"10.1111","volume":"207","author":[{"given":"Sebastian","family":"Patzke","sequence":"first","affiliation":[{"name":"SpinChip Diagnostics AS  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Cascione","sequence":"additional","affiliation":[{"name":"Faculty of Biomedical Sciences, Institute of Oncology Research USI  Bellinzona Switzerland"},{"name":"SIB Swiss Institute of Bioinformatics  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine B.","family":"Melhus","sequence":"additional","affiliation":[{"name":"Institute for Energy Technology  Kjeller Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Munz","sequence":"additional","affiliation":[{"name":"Faculty of Biomedical Sciences, Institute of Oncology Research USI  Bellinzona Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Arribas","sequence":"additional","affiliation":[{"name":"Faculty of Biomedical Sciences, Institute of Oncology Research USI  Bellinzona Switzerland"},{"name":"SIB Swiss Institute of Bioinformatics  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Faculty of Biomedical Sciences, Institute of Oncology Research USI  Bellinzona Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Generalov","sequence":"additional","affiliation":[{"name":"Artbio AS  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada H. V.","family":"Repetto\u2010Llamazares","sequence":"additional","affiliation":[{"name":"Nuclithera  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-6005","authenticated-orcid":false,"given":"Jostein","family":"Dahle","sequence":"additional","affiliation":[{"name":"Department of Oncology Akershus University Hospital  L\u00f8renskog Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-8983","authenticated-orcid":false,"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[{"name":"Faculty of Biomedical Sciences, Institute of Oncology Research USI  Bellinzona Switzerland"},{"name":"Oncology Institute of Southern Switzerland  Bellinzona Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3925"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121126"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1322577"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4101"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0067"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-505685"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-748137"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1985.tb01422.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx541"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310213291702"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0570-4"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13099"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012291"},{"issue":"1","key":"e_1_2_11_16_1","article-title":"CD20 expression regulates CD37 levels in B\u2010cell lymphoma\u2014implications for immunotherapies","volume":"13","author":"Bobrowicz M","year":"2024","journal-title":"Onco Targets Ther"},{"issue":"1","key":"e_1_2_11_17_1","first-page":"85","article-title":"Evaluating antigen targeting and anti\u2010tumor activity of a new anti\u2010CD37 radioimmunoconjugate against non\u2010Hodgkin's lymphoma","volume":"33","author":"Dahle J","year":"2013","journal-title":"Anticancer Res"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-025-00096-w"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/61\/19\/6935"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128816"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0677-4"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01301"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002583"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847528.94329.37"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.227215"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1041"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0477"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1947"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2019.01.003"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpb.2022.01.004"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284197"},{"issue":"4","key":"e_1_2_11_33_1","first-page":"1022","article-title":"More than a lonca\u2010shot: beating the odds in relapsed\/ refractory diffuse large B\u2010cell lymphoma","volume":"109","author":"Ho C","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01583"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-018-0410-3"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3118"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2007.06.006"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201310"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-19-0059"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092409"},{"issue":"11","key":"e_1_2_11_42_1","first-page":"2387","article-title":"Relationships between G1 arrest and stability of the p53 and p21Cip1\/Waf1 proteins following gamma\u2010irradiation of human lymphoma cells","volume":"55","author":"Bae I","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.2307\/3579680"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-067579"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70143","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:09:46Z","timestamp":1783015786000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/bjh.70143"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70143","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"2025-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}